bb2121 is a new treatment being investigated in myeloma that belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. This involves T-cells being taken from the patient and being changed to find myeloma cells more easily. When it finds myeloma cells, bb2121 removes and destroys them.

SparkCures ID 236
Developed By bluebird bio
Generic Name bb2121
Additional Names idecabtagene vicleucel (ide-cel)
Treatment Classifications
Treatment Targets

Clinical Trials

Published Results

BB2121 CAR T Results Described in New England Journal of Medicine

May 08, 2019

In the Phase I study, 33 patients with relapsed or refractory myeloma were giving bb2121 as a single infusion of the CAR T product at different doses in the dose escalation phase (50×106, 150×106, 450×106, or 800×10). Two of of those doses (150×106 to 450×106) were used in the expansion phase. Patients who participated had received at least three prior lines of treatment and their myeloma had become resistant to both a proteasome inhibitor and an immunomodulator. As in all phase I studies, the goal is to assess safety.

The following data was gathered up until 6.2 months after the last patient’s infusion date:

  • The objective response rate was 85%. Fifteen patients (45%) had complete responses and six of these 15 have relapsed.
  • Sixteen patients who had a partial response or better were tested for minimal residual disease (MRD) and had MRD negative status.
  • The median progression-free survival was 11.8 months.
  • The CAR T cells persisted up to 1 year after the infusion.